Research programme: flavonoid anti-inflammatory molecules - Kazia Therapeutics
Latest Information Update: 12 Dec 2017
At a glance
- Originator Novogen
- Developer Kazia Therapeutics
- Class Flavonoids
- Mechanism of Action Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Australia (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Australia (PO)
- 07 Mar 2011 Preclinical development is ongoing in Australia